Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-05. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
The actual chain elongation occurs through condensation between malonyl-mtACP and the growing acyl-mtACP (with acetyl-mtACP in the first round) by 3-oxoacyl-ACP synthase (OXSM), releasing CO2 and extending the chain by two carbons. Next, the newly extended fatty acyl chain on mtACP (3-ketoacyl-mtACP) undergoes reduction by the mitochondrial 3-ketoacyl-ACP reductase (mtKAR; composed of HSD17B8 and CBR4), dehydration by 3-hydroxyacyl-ACP dehydratase 2 (HTD2), and a final reduction by trans-2-enoyl-CoA reductase (MECR). The last three steps restore the fatty acyl chain to its saturated state prior to condensation, making it available for the next elongation cycle. NADPH, the electron donor required for the reduction steps, fuels the mtFAS pathway and is derived from NADP+ produced by NADK2. These steps repeat until the required chain length is reached, generating mtACP-bound fatty acyl chains ranging from C2 to C16. Since no mitochondrial acyl-mtACP thioesterase has been identified in any animal species, the final products of mtFAS remain bound to mtACP rather than being released as free fatty acids.
== Selectivity coefficient == The concept of selectivity is used to quantify the extent to which one chemical substance, A, binds each of two other chemical substances, B and C. The simplest case is where the complexes formed have 1:1 stoichiometry. Then, the two interactions may be characterized by equilibrium constants KAB and KAC.
The Chanka people lived in the Huancavelica, Ayacucho, and Apurímac regions of Peru. The Huanca people of the Junín Region of Peru spoke Quechua before the Incas did. The Inca established the largest empire of the pre-Columbian era. The Chincha, an extinct merchant kingdom of the Chincha Islands of Peru. The Qolla inhabited the Potosí, Oruro, and La Paz departments of Bolivia. The Cañari of Ecuador adopted the Quechua language from the Inca. The speakers of Quechua total some 5.1 million people in Peru, 1.8 million in Bolivia, 2.5 million in Ecuador (Hornberger and King, 2001), and according to Ethnologue (2006) 33,800 in Chile, 55,500 in Argentina, and a few hundred in Brazil. Only a slight sense of common identity exists among these speakers spread all over Peru, Bolivia and Ecuador. The various Quechua dialects are in some cases so different from one another that mutual understanding is not possible. Quechua was spoken not only by the Incas, but also by long-term enemies of the Inca Empire, including the Huanca (Wanka is a Quechua dialect spoken today in the Huancayo area) and the Chanka (the Chanca dialect of Ayacucho) of Peru, and the Kañari (Cañari) in Ecuador. Quechua was spoken by some of these people, for example, the Wanka, before the Incas of Cusco, while other people, especially in Bolivia but also in Ecuador, adopted Quechua only in Inca times or afterward. Some Christian organizations also refer to a "Quechua people", such as the Christian shortwave radio station HCJB, "The Voice of the Andes" (La Voz de los Andes).
Refers to trials to find better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes. (NLM) Preventive
Sources: en.wikipedia.org
alkane Also paraffin. Any fully saturated acyclic hydrocarbon,An acyclic saturated hydrocarbon containing only carbon and hydrogen atoms with only single carbon–carbon bonds; alkanes generally have the formula CnH2n+2. i.e. one in which all carbon–carbon bonds are single bonds.
=== Biosensors === Aminopeptidases have been utilized in creating biosensors for detecting specific amino acids or peptides. These biosensors generate a measurable signal in the presence of the target analyte, leveraging the catalytic activity of aminopeptidases.
For example, it has been argued that lanthanum and actinium cannot be f-block elements because as individual gas-phase atoms, they have not begun to fill the f-subshells. But the same is true of thorium which is never disputed as an f-block element, and this argument overlooks the problem on the other end: that the f-shells complete filling at ytterbium and nobelium, matching the Sc-Y-Lu-Lr form, and not at lutetium and lawrencium as the Sc-Y-La-Ac form would have it. Not only are such exceptional configurations in the minority, but they have also in any case never been considered as relevant for positioning any other elements on the periodic table: in gaseous atoms, the d-shells complete their filling at copper, palladium, and gold, but it is universally accepted by chemists that these configurations are exceptional and that the d-block really ends in accordance with the Madelung rule at zinc, cadmium, and mercury. The relevant fact for placement is that lanthanum and actinium (like thorium) have valence f orbitals that can become occupied in chemical environments, whereas lutetium and lawrencium do not: their f-shells are in the core, and cannot be used for chemical reactions. Thus the relationship between yttrium and lanthanum is only a secondary relationship between elements with the same number of valence electrons but different kinds of valence orbitals, such as that between chromium and uranium; whereas the relationship between yttrium and lutetium is primary, sharing both valence electron count and valence orbital type.
Sources: en.wikipedia.org
The results are clear cut, and show that penicillin is active in vivo against at least three of the organisms inhibited in vitro. It would seem a reasonable hope that all organisms in high dilution in vitro will be found to be dealt with in vivo. Penicillin does not appear to be related to any chemotherapeutic substance at present in use and is particularly remarkable for its activity against the anaerobic organisms associated with gas gangrene. The publication attracted little attention; Florey would spend much of the next two years attempting to convince people of the significance of their results. One reader was Fleming, who paid them a visit on 2 September 1940. Florey and Chain gave him a tour of the production, extraction and testing laboratories, but he made no comment and did not congratulate them on the work they had done. Some members of the Oxford team suspected that he was trying to claim some credit for it. Unbeknown to the Oxford team, their Lancet article was read by Martin Henry Dawson, Gladys Hobby and Karl Meyer at Columbia University, and they were inspired to replicate the Oxford team's results. They obtained a culture of Penicillium mould from Roger Reid at Johns Hopkins Hospital, grown from a sample he had received from Fleming in 1935. They began growing the mould on 23 September, and on 30 September tested it against viridans streptococci, and confirmed the Oxford team's results. Meyer duplicated Chain's processes, and they obtained a small quantity of penicillin.
In 2014, Buc-ee's filed a lawsuit against Texas-based convenience store chain "Frio Beaver". Frio Beaver, a company with a logo also depicting a beaver in a yellow circle with a black outline, was accused of copying the Buc-ee's beaver head logo, which the company is widely known for in Texas. The case was settled out of court in December 2014; B&B Grocery Inc. agreed to stop using the "Frio Beaver" logo and mascot. In 2016, Buc-ee's sued "Choke Canyon BBQ", another Texas convenience store, for copyright infringement and trade dressing. Choke Canyon used a logo of a grinning alligator in the middle of a yellow circle, which Buc-ee's claimed was an attempt by the chain to resemble the Buc-ee's logo. Choke Canyon was also calling its new stores "Bucky's". Choke Canyon lost the federal lawsuit in May 2018, with Choke Canyon changing its logo to a cowboy inside of an orange circle. In 2017, Buc-ee's again filed a lawsuit for breaking an agreement, this time against a Nebraska-based convenience store chain known as "Bucky's". The two companies had agreed to remain in their respective states and expand only to states where the other did not operate. The lawsuit was thrown out. A non-logo related lawsuit was filed in 2013 against "Chicks", a convenience store in Bryan, Texas, for trade dress violations by allegedly copying Buc-ee's mega convenience store designs and layout. The case was settled out of court.
Gankyrin, a recently identified oncoprotein, is one of the 19S subcomponents that also tightly binds the cyclin-dependent kinase CDK4 and plays a key role in recognizing ubiquitinated p53, via its affinity for the ubiquitin ligase MDM2. Gankyrin is anti-apoptotic and has been shown to be overexpressed in some tumor cell types such as hepatocellular carcinoma. Like eukaryotes, some archaea also use the proteasome to control cell cycle, specifically by controlling ESCRT-III-mediated cell division.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.